Identification of patients with high risk of micro-metastases by biomarkers as, for example, ANXA10 may facilitate usage of neoadjuvant chemotherapy both as early treatment of metastasis and as treatment of metastatic disease while the burden of disease is low. The gene discussed is ANXA10; the disease is metastatic neoplasm.